生长抑素联合血必净治疗急性胰腺炎的临床效果

目的探讨生长抑素联合血必净治疗急性胰腺炎的临床效果。方法选取2017年5月至2020年6月广西壮族自治区全州县人民医院重症医学科收治的88例急性胰腺炎患者,将其随机分为A组和B组,各44例。A组给予生长抑素治疗,B组在A组基础上给予血必净治疗。比较两组不同时间点的降钙素原(PCT)、C反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)、血清脂肪酶、血清淀粉酶水平、重症监护室住院时间、并发症(肺部感染、急性呼吸窘迫综合征、胰腺假性囊肿、急性肾衰竭、脓毒血症)发生情况、28 d死亡率。结果T₁时,两组的PCT、CRP、TNF-α、IL-6、血清脂肪酶、血清淀粉酶水平比较,差异无统计学意义(P>0.05);T₂~T₄时,B组的PCT、CRP、TNF-α、IL-6、血清脂肪酶、血清淀粉酶水平低于A组,差异具有统计学意义(P<0.05)。B组的重症监护室住院时间短于A组,肺部感染、急性呼吸窘迫综合征、胰腺假性囊肿、急性肾衰竭、脓毒血症发生率及28 d死亡率低于A组,差异具有统计学意义(P<0.05)。结论生长抑素联合血必净可明显改善急性胰腺炎患者的临床相关指标水平,缩短重症监护室住院时间,降低并发症发生率及28 d死亡率,值得临床推广应用。

Clinical effect of somatostatin combined with Xuebijing in the treatment of acute pancreatitis

Objective To investigate the clinical effect of somatostatin combined with Xuebijing in the treatment of acute pancreatitis.Methods A total of 88 patients with acute pancreatitis treated in the intensive care unit of Quanzhou people's hospital of Guangxi Zhuang Autonomous region from May 2017 to June 2020 were selected and randomly divided into group A and group B,with 44 cases in each group.The group A was treated with somatostatin,and the group B was treated with Xuebijing on the basis of the group A.The procalcitonin(PCT),C-reactive protein(CRP),tumor necrosis factor-α(TNF-α),interleukin-6(IL-6),serum lipase,serum amylase levels at different points,length of stay in intensive care unit,occurrence of complications(pulmonary infection,acute respiratory distress syndrome,pancreatic pseudocyst,acute renal failure,septicopyemia)and 28 d mortality rate were compared between the two groups.Results At T₁,there were no significant differences in the PCT,CRP,TNF-α,IL-6,serum lipase,serum amylase levels between the two groups(P>0.05);At T₂-T₄,PCT,CRP,TNF-α,IL-6,serum lipase,serum amylase levels in the group B were lower than those in the group A,and the differences were statistically significant(P<0.05).The length of stay in intensive care unit in the group B was shorter than that in the group A,and the incidence of pulmonary infection,acute respiratory distress syndrome,pancreatic pseudocyst,acute renal failure,septicopyemia and 28 d mortality rate in the group B were lower than those in the group A,and the differences were statistically significant(P<0.05).Conclusion Somatostatin combined with Xuebijing can significantly improve the levels of clinical related indexes in patients with acute pancreatitis,shorten the length of stay in intensive care unit,reduce the incidence of complications and 28 d mortality rate.It is worthy of clinical promotion and application.